Optimizing Patient Selection & Prediction of Therapy Efficacy in
Clinical Trials with ctDNA

Tuesday June 14 | 6pm - 8pm ET | Boston, MA | In-Person Event Only

This is an exclusive event created to provide senior pharma leaders with the opportunity to hear from fellow pharma stakeholders and researchers on how they are using circulating tumor DNA (ctDNA) to optimize and accelerate oncology therapeutic development. Discover the latest biomarker strategies leveraging ctDNA to:

  • Stratify & enrich for patients most likely to benefit from additional therapy to maximize treatment benefit and decrease the necessary study size
  • Monitor therapy response for early prediction of therapy efficacy to support program prioritization
  • Support accelerated approval of new therapeutics as a potential surrogate endpoint

Join us for an insightful panel discussion among pharma Directors, VPs and Functional Heads within the translational, clinical development, and diagnostics arenas, and connect over a few appetizers and drinks!



Please Note: This is an in-person event only, and online attendance will not be available!

Having trouble registering? Email: info@hansonwade.com

*Attendance is subject to final approval from the event organizers


Natera_Logo (1)

Natera has developed Signatera, a tumor-informed circulating tumor DNA (ctDNA) test, capable of detecting the presence of molecular residual disease (MRD) down to a single tumor molecule in a tube of blood.
With 20+ peer-reviewed publications and 60+ presentations, Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers. Signatera is being used in multiple prospective studies, received CMS Local Coverage Determination for immunotherapy monitoring and Stage II-IV colorectal cancer, and is available to biopharmaceutical customers and clinicians globally.

Look deeper at: